FOSHAN, GUANGDONG, CHINA, January 14, 2026 /EINPresswire.com/ -- Foshan AoChuanShun New Material Industrial Co., Ltd.

BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated ...

Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and is approved and ...

Worldcoin faces scrutiny, Pi Network unlocks supply, while ZKP spends $17M on failure protection. A timing‑driven comparison ...

Middle East envoy Steve Witkoff said the second phase entailed “demilitarization, technocratic governance, and reconstruction ...

Middle East envoy Steve Witkoff said the second phase entailed “demilitarization, technocratic governance, and reconstruction ...

The latest announcement is out from Insmed ( (INSM)). On December 17, 2025, Insmed announced the Phase 2b BiRCh study of brensocatib for chronic rhinosinusitis without nasal polyps (CRSsNP) did not ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 2 CADENCE study evaluating WINREVAIR™ ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 2 CADENCE study evaluating WINREVAIR™ (sotatercept-csrk) in adults for ...

Two Sarepta Therapeutics drugs for treating different genetic subsets of patients with Duchenne muscular dystrophy failed the confirmatory study required of their accelerated FDA approvals. Sarepta ...

Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, QDENGA® (Dengue ...